AIDS

1. THORNHILL JP, Fox J, Martin GE, Hall R, et al
   Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
   AIDS. 2023 Dec 21. doi: 10.1097/QAD.0000000000003825.
   

   >> Share

   
   
2. HOLDEN CJ, Lampe FC, Burns FM, Chaloner C, et al
   Association of age at ART initiation with CD4:CD8 ratio recovery among virally suppressed people living with HIV, 2001-2019.
   AIDS. 2023 Nov 28. doi: 10.1097/QAD.0000000000003801.
   

   >> Share

   
   

   
   Antimicrob Agents Chemother

3. WANG C, Yu X, Ke Y, Fu Y, et al
   Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
   Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
   

   >> Share

   
   

   
   Clin Infect Dis

4. LANDOVITZ RJ, Tao L, Yang J, de Boer M, et al
   HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
   Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093.
   

   >> Share

   
   
5. LLIBRE JM, Jou A, Puig T
   High-level dolutegravir resistance selection on dolutegravir/lamivudine.
   Clin Infect Dis. 2024 Mar 11:ciae125. doi: 10.1093.
   

   >> Share

   
   

   
   J Acquir Immune Defic Syndr

6. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
   Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
   J Acquir Immune Defic Syndr. 2024;95:e8-e11.
   

   >> Share

   
   

   
   J Med Virol

7. YANG J, Xu S, Cheng J, Yin X, et al
   CXCL10 and its receptor in patients with chronic hepatitis B and their ability to predict HBeAg seroconversion during antiviral treatment with TDF.
   J Med Virol. 2024;96:e29516.
   

   >> Share

   
   

   
   Lancet

8. KANKASA C, Mennecier A, Sakana BLD, Moles JP, et al
   Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.
   Lancet. 2024 Mar 11:S0140-6736(23)02464-9. doi: 10.1016/S0140-6736(23)02464.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share